Anthony Giovinazzo

  • President and Chief Executive Officer
  • Cynapsus Therapeutics
  • Toronto, ON   
  • Website


Contact me for: New developments in treatments for Parkinson’s disease symptoms

Mr. Giovinazzo is a Director and the President and Chief Executive Officer of the Corporation. He is an experienced Biotech CEO with more than 18 years of experience in international pharmaceutical drug development, private and public financings, and M&A transactions. He has identified, licensed, and overseen the development of eight biotech drug development candidates, pre-clinical to Phase 3, for the treatment of Parkinson’s, Alzheimer’s, anxiety, neuropathic pain, and nausea. Mr. Giovinazzo led the sale of Nova Molecular Diagnostics to Variagenics Inc. through the public listing of Variagenics that resulted in significant above-average returns to investors. As CEO, he also led the acquisition of Cita Neuropharmaceuticals by Vernalis Plc., which resulted in a substantial multiple return to venture investors. Mr. Giovinazzo holds a Chartered Director (C.Dir.) and Audit Committee Certification (A.C.C.) from The Director’s College, where he is also a faculty member. He is also a business advisory board member of the National Research Council of Canada’s Genomics funding program and is on the Board and is Chair of the Audit Committee of Majescor Resources Inc (TSX-V: MJX). He is one of the inventors of the original APL-130277 intellectual property that was acquired by the Corporation.

Expert Articles by Anthony Giovinazzo

Aging and Longevity

Help managing Parkinson's disease symptoms and getting treatment

Contact Anthony Giovinazzo

Message was successfully sent. There was an error sending the message.